ACS Medicinal Chemistry Letters
Letter
(3) Simon, J. A.; Lange, C. A. Roles of the EZH2 Histone
Methyltransferase in Cancer Epigenetics. Mutat. Res. 2008, 647, 21−
29.
(14) Garapaty-Rao, S.; Nasvechuk, C.; Gagnon, A.; Chan, E. Y.;
Sandy, P.; Busby, J.; Balasubramanian, S.; Campbell, R.; Zhao, F.;
Bergeron, L.; Audia, J. E.; Albrecht, B. K.; Harmange, J.-C.; Cummings,
R.; Trojer, P. Identification of EZH2 and EZH1 Small Molecule
Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma
Cell Growth. Chem. Biol. 2013, 20, 1329−1339.
(15) Nasveschuk, C. G.; Gagnon, A.; Garapaty-Rao, S.;
Balasubramanian, S.; Campbell, R.; Lee, C.; Zhao, F.; Bergeron, L.;
Cummings, R.; Trojer, P.; Audia, J. E.; Albrecht, B. K.; Harmange, J.-C.
P. Discovery and Optimization of Tetramethylpiperidinyl Benzamides
as Inhibitors of EZH2. ACS Med. Chem. Lett. 2014, 5, 378−383.
(16) As calculated using ChemAxon JChem for Excel software.
(4) Knutson, S. K.; Warholic, N. M.; Wigle, T. J.; Klaus, C. R.; Allain,
C. J.; Raimondi, A.; Porter-Scott, M.; Chesworth, R.; Moyer, M. P.;
Copeland, R. A.; Richon, V. M.; Pollock, R. M.; Kuntz, K. W.;
Keilhack, H. Durable Tumor Regression in Genetically Altered
Malignant Rhabdoid Tumors by Inhibition of Methyltransferase
EZH2. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 7922−7927.
(5) Sneeringer, C. J.; Porter-Scott, M.; Kuntz, K. W.; Knutson, S. K.;
Pollock, R. M.; Richon, V. R.; Copeland, R. A. Coordinated activities
of wild-type plus mutant EZH2 drive tumor-associated hyper-
trimethylation of lysine 27 on histone H3 (HEK27) in human B cell
Lymphomas. Proc. Natl. Acad. Sci. U.S.A. 2011, 107, 20980−20985.
(6) Knutson, S. K.; Warholic, N. M.; Johnston, L. D.; Klaus, C. R.;
Wigle, T. J.; Iwanowicz, D.; Littlefield, B. A.; Porter-Scott, M.; Smith,
J.; Moyer, M. P.; Copeland, R. A.; Pollock, R. M.; Kuntz, K. W.;
Raimondi, A.; Keilhack, H. Synergistic Anti-Tumor Activity of EZH2
Inhibitors and Glucocoericoid Receptor Agonists in Models of
Germinal Center Non-Hodgekin Lymphomas. PLoS One 2014, 9,
e111840.
(7) Ntziachristos, P.; Tsirigos, A.; Van Vlierberghe, P.; Nedjic, J.;
Trimarchi, T.; Sol Flaherty, M.; Ferres-Marco, D.; da Ros, V.; Tang,
Z.; Siegle, J.; Asp, P.; Hadler, M.; Rigo, I.; De Keersmaecker, K.; Patel,
J.; Huynh, T.; Utro, F.; Poglio, S.; Samon, J. B.; Paietta, E.; Recevskis,
J.; Rowe, J. M.; Rabadan, R.; Levine, R. L.; Brown, S.; Pflumio, F.;
Dominguez, M.; Ferrando, A.; Aifantis, I. Genetic inactivation of the
polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Nat. Med. 2012, 18, 298−303.
(8) Wang, S.; Robertson, G. P.; Zhu, J. A novel human homologue of
Drosophila polycomblike gene is up-regulated in multiple cancers.
Gene 2004, 343, 69−78.
(9) Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.;
Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.;
Song, J.; Porter-Scott, M.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth,
R.; Moyer, M.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock,
R. M.; Kuntz, K. W. A Selective Inhibitor of EZH2 blocks H3K27
methylation and Kills Mutant Lymphoma Cells. Nat. Chem. Biol. 2012,
8, 890−896.
(10) Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.;
MacNevin, C. J.; Liu, F.; Gao, C.; Huang, X.-P.; Kuznetsova, E.;
Rougie, M.; Jiang, A.; Patterden, S. G.; Norris, J. L.; James, L. I.; Roth,
B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang,
G. G.; Vedadi, M.; Jin, J. An Orally Bioavailable Chemical Probe of the
Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 2013, 8,
1324−1334.
(11) Verma, S. K.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez,
D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.;
Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.;
Ott, H. M.; Van Aller, G. S.; Machutta, C. A.; Diaz, E.; Jiang, Y.;
Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak,
D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of
Potent, Selective Cell-Active Inhibitors of the Histone Lysine
Methyltransferase EZH2. ACS Med. Chem. Lett. 2012, 3, 1091−1096.
(12) Qi, W.; Chan, H.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.;
Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J.-H.; Yan, X.;
Fang, J.; Mi, Y.; Zhang, M.; Zhao, T.; Feng, G.; Chen, Z.; Li, G.; Ynag,
T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C. X.; Atadja, P.; Li, E. Selective
inhibition of EZH2 by a small molecule inhibitor blocks tumor cell
proliferation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 21360−21365.
(13) Bradley, W. D.; Arora, S.; Busby, J.; Balasubramanian, S.;
Gehling, V.; Nasveschuk, C. G.; Vaswani, R. G.; Yuan, C.-C.; Hatton,
́
C.; Zhao, F.; Williamson, K. E.; Iyer, P.; Mendez, J.; Campbell, R.;
Cantone, N.; Garapaty-Rao, S.; Audia, J.; Cook, A. S.; Dakin, L. A.;
Albrecht, B. K.; Harmange, J.-C.; Daniels, D. L.; Cummings, R. T.;
Bryant, B. M.; Normant, E.; Trojer, P. EZH2 Inhibitor Efficacy in
Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27
Monomethylation. Chem. Biol. 2014, 21, 1463−1475.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX